Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | ACACA | Q13085 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7680702 | 1.00 | BTK (0.61) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL7246825 | 1.00 | BTK (0.61) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL8141945 | 1.00 | BTK (0.61) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL4354977 | 0.91 | KMT2A (0.60) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL4346477 | 0.91 | KMT2A (0.60) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL6641586 | 0.91 | KMT2A (0.60) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL6641585 | 0.91 | KMT2A (0.60) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL25036375 | 0.89 | KMT2A (0.64) | BTKKMT2ASMN1; SMN2EPHX1CTSS | |
| SCHEMBL6647123 | 0.88 | EPHX1 (0.48) | BTKKMT2AEPHX1CTSSCTSK | |
| SCHEMBL5507221 | 0.87 | BTK (0.46) | BTKKMT2ASMN1; SMN2EPHX1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-10-18 | — | — | US | disclosed |
| CN-101035785-A | Novel compounds having an anti-bacterial activity | MORPHOCHEM AG KOMB CHEMIE (DE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-6613769-B1 | Incubating samples with enzyme inhibitors, then determining complexes formed; medical diagnosis; therapy for allergies and inflammation | Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. (DE) | 2003-09-02 | — | — | US | disclosed |
| US-6489327-B1 | TREATING A DISEASE SUSCEPTIBLE TO TRYPTASE INHIBITION SUCH AS ASTHMA, INFLAMMATORY BOWEL DISEASE, PSORIASIS OR RHINITIS | MAX-PLANCK-GESELLSCHAFT ZUR FORDRUNGDER WISENSCHAFTEN, E.V. (DE) | 2002-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | BTK 3312/4885KMT2A 4690/4885SMN1; SMN2 3692/4885 |
| US-20070244103-A1 | Novel Compounds Having an Anti-Bacterial Activity | TOP1, TOP2A, TOP2B | BTK 3036/4885KMT2A 2689/4885SMN1; SMN2 4778/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | BTK 3312/4885KMT2A 4690/4885SMN1; SMN2 3692/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | BTK 3312/4885KMT2A 4690/4885SMN1; SMN2 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.